What You Ought to Know:
– Immunai, a number one AI biotech firm specializing in mapping the human immune system and the Parker Institute for Most cancers Immunotherapy (PICI), a collaborative consortium of the world’s main immuno-oncology consultants, introduced right this moment that they’ll construct the world’s largest single-cell dataset from sufferers handled with standard-of-care (SoC) immunotherapy.
– Underneath the collaboration with PICI, Immunai will carry out single-cell RNA sequencing (scRNA-seq) and multi-omic profiling of affected person blood samples collected from PICI’s RADIOHEAD (Resistance Drivers for Immuno-Oncology Sufferers Interrogated by Harmonized Molecular Datasets) cohort, a potential longitudinal research of 1,070 sufferers receiving immune checkpoint inhibitor therapy regimens in a group setting.
Immunai Expands AMICA™ with Trade’s Largest Actual-World Single-Cell Dataset in Immuno-Oncology
Immunai, a biotechnology firm leveraging single-cell genomics and machine studying to rework therapeutic improvement, has introduced a significant enlargement of its AMICA™ (Annotated Multi-omic Immune Cell Atlas) platform. This enlargement will combine the most important single-cell dataset of standard-of-care (SoC) comparators in immuno-oncology, considerably enhancing AMICA’s benchmarking energy and translational relevance.
The initiative makes use of 10x Genomics’ Chromium GEM-X single-cell know-how to assist high-throughput, cost-effective pattern processing, enabling the era of high-quality single-cell information at scale. This dataset will likely be totally embedded inside AMICA™, strengthening its analytical capabilities and positioning it as probably the most complete immune cell atlas obtainable for oncology analysis.
The expanded dataset will broaden entry to immunotherapy response profiles throughout a various vary of tumor sorts—together with non-small cell lung most cancers (NSCLC), small cell lung most cancers (SCLC), gastric most cancers, hepatocellular carcinoma (HCC), and melanoma. This may assist the identification of clinically distinct affected person subgroups by:
- facilitating the invention of predictive biomarkers,
- enabling deeper understanding of mechanisms of motion and resistance,
- and bettering characterization of affected person responses in real-world contexts.
By integrating hundreds of real-world samples, AMICA™ gives a extra consultant view of immune responses, closing the hole between managed medical trials and routine medical apply. Its embedded machine studying instruments additional speed up insights from this information, guiding drug builders in figuring out not solely which sufferers are probably to learn from rising therapies but in addition the place therapies could also be ineffective or require modification.
“There’s a giant hole between what we be taught in managed trials and what occurs in real-world affected person care,” stated Noam Solomon, PhD, CEO and Co-Founding father of Immunai. “By including hundreds of real-world samples to AMICA, we’re giving scientists and drug builders the facility to identify the affected person teams probably to learn from new therapies—and maybe extra importantly, the place they won’t.”
With over 170 workforce members, together with 85 PhDs and MDs, and near $270 million in funding, Immunai continues to collaborate with main pharmaceutical firms and educational establishments. Headquartered in New York Metropolis, the corporate stays on the forefront of unlocking the immune system’s potential to information precision therapies by means of data-driven discovery.